Vinorelbine
- Generic Name
- Vinorelbine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C45H54N4O8
- CAS Number
- 71486-22-1
- Unique Ingredient Identifier
- Q6C979R91Y
- Background
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
...
- Indication
Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .
Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .
...
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma
- Associated Therapies
- -
A Trial of Gemcitabine Combined With Vinorelbine as First Line Chemotherapy for Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2007-08-31
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 80
- Registration Number
- NCT00192062
- Locations
- 🇪🇬
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Monday-Friday from 9:00 AM to 5:00 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician, Giza, Egypt
Effects of Granulocyte Colony-stimulating Factor (G-CSF), Trastuzumab, and Vinorelbine on Immune Cell Function
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2018-07-20
- Lead Sponsor
- Dartmouth-Hitchcock Medical Center
- Target Recruit Count
- 23
- Registration Number
- NCT00169104
Study for Patients With Non Small Cell Lung Cancer (NSCLC)
- Conditions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2006-11-01
- Lead Sponsor
- Charite University, Berlin, Germany
- Target Recruit Count
- 80
- Registration Number
- NCT00168883
- Locations
- 🇩🇪
Hematology & Oncology Charité CBF Berlin, Berlin, Germany
Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-03-23
- Target Recruit Count
- 31
- Registration Number
- NCT00176488
- Locations
- 🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2013-02-07
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00153907
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Preoperative Herceptin and Navelbine for Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2019-01-15
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 49
- Registration Number
- NCT00148681
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Center, Boston, Massachusetts, United States
Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/Herceptin in HER-2 Positive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2013-04-09
- Lead Sponsor
- Eric Winer, MD
- Target Recruit Count
- 81
- Registration Number
- NCT00148668
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy.
- Conditions
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2008-04-22
- Lead Sponsor
- Aktion Bronchialkarzinom e.V.
- Target Recruit Count
- 280
- Registration Number
- NCT00148395
- Locations
- 🇩🇪
Klinikum Kassel GmbH, Kassel, Germany
Oral Estramustine and Oral Vinorelbine in the Treatment of Hormone-Refractory Prostate Cancer
- First Posted Date
- 2005-09-08
- Last Posted Date
- 2015-01-22
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT00151086
- Locations
- 🇺🇸
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Trastuzumab in Combination With Vinorelbine or Taxane-Based Chemotherapy in Patients With Metastatic Breast Cancer
- Conditions
- First Posted Date
- 2005-09-07
- Last Posted Date
- 2009-11-01
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 250
- Registration Number
- NCT00146549
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.